Farzana Muhib

Program Officer
Phone: 
+1.202.470.5731

Farzana Muhib joined Results for Development Institute in May 2008. She currently works on the aids2031 Costs and Financing Working Group and is responsible for the management of project activities. Before joining R4D, she worked at Johns Hopkins University on the Pneumococcal Vaccine Accelerated Development and Introduction Project as the Research Project Manager coordinating over 40 research and surveillance projects. Ms. Muhib has extensive international experience and has worked in South and South West Asia. She served as the PneumoADIP’s focal point for the EMRO region on pneumococcal vaccine, and helped to set up surveillance for pneumococcal disease in several countries including Mongolia and Pakistan. Ms. Muhib has also worked on domestic health issues during her time at the Centers for Disease Control, where she was a survey coordinator for a National HIV/AIDS Behavioral Research project. She also developed a technical assistance manual for state and local health departments to conduct rapid assessments of HIV/AIDS risk behaviors.

Ms. Muhib holds a Masters in Public Health from the Rollins School of Public Health at Emory University, where she concentrated in International Health and Epidemiology. She also obtained her Masters of Arts in Law and Diplomacy from the Fletcher School of Law and Diplomacy at Tufts University, focusing on Development Economics and South West Asian Civilizations.

Related News

In preparation for World AIDS Day, the BBC invited Farzana Muhib, R4D's coordinator for the aids2031 Costs and Financing Project, to discuss future cost and financing scenarios for the global AIDS epidemic in their Health Check spotlight, "The Future for HIV/AIDS Funding."  Ms. Muhib highlighted the importance of "tough choice" spending policy decisions and more efficient management of resources now in order to curb future costs of the epidemic and achieve better health outcomes.

Related Publiations & Resources

This paper examines potential long-term costs and financing options for the global AIDS response under four different scenarios and provides policy recommendations based on projected epidemiological and financial impacts.

This paper incorporates results from several of the aids2031 working groups to examine the costs and financial implications of changing the current approach to fighting HIV/AIDS.  It examines four different scenarios: Current Trends, Rapid Scale-up, Hard Choices for Prevention and Structural Change.

This paper assesses the costs of antiretroviral drug (ARV) procurement and identifies policies that could help to lower costs, improve efficiency, and thereby ensure sustainable long-term access to ARVs by low and middle income countries.